Hims & Hers falls 8% as FDA issues warning letter over compounded weight loss drug

Press Room

9 hours ago

aprott/iStock via Getty Images

Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design — aprott/iStock via Getty Images

The U.S. FDA has issued a warning letter to Hims & Hers Health (NYSE:HIMS) over its marketing of compounded semaglutide, the weight loss drug marketed under the brand name Wegovy by Novo Nordisk (NVO).
Shares of Hims & Hers are

Exit mobile version